Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.
A Prospective, Randomized, Double-blind Controlled Trial of Chlorpheniramine Pretransfusion Medication for Allergic Transfusion Reactions
Institute of Hematology & Blood Diseases Hospital, China
6,642 participants
Jan 1, 2021
INTERVENTIONAL
Conditions
Summary
This is a prospective, randomized, double-blind controlled trial to evaluate the efficacy of placebo versus chlorpheniramine for the prevention of allergic transfusion reactions.
Eligibility
Inclusion Criteria3
- \~65 years old.
- Subject is diagnosed with hematological disorder and requires blood product (i.e. suspended red blood cells, apheresis platelets, fresh frozen plasma) transfusions.
- Subject can fully understand and voluntarily sign informed consent forms.
Exclusion Criteria9
- Subject with a history of allergic diseases.
- Subject experienced at least 1 moderate/severe or 2 mild allergic reactions in the past.
- Subject received glucocorticoid or allergy drugs within 24 hours before blood transfusion.
- Subject transfused with washed RBC.
- Received allo-HSCT transplantation before.
- Subject with heart failure.
- Subject suffered from sequelae of cardiovascular or cerebrovascular diseases.
- Pregnant or nursing women.
- Inability to understand or to follow study procedures.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The tablet resembles chlorpheniramine but has no therapeutic value.
An antihistamine that reduces the natural chemical histamine in the body.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04688736